SUMMARY The effects of hyperbaric oxygen at a pressure of two atmospheres absolute were studied in a group of patients with chronic progressive multiple sclerosis. A slight but statistically insignificant shortening of the visual evoked potential latencies was seen after treatment with hyperbaric oxygen as compared with placebo treatment. The treatment did not appreciably halt the progression of the disease and deterioration occurred more often among the patients in the treatment group than in the control group.
The absence of an effective treatment for multiple sclerosis has led to investigation of hyperbaric oxygen as a possible means of modifying features of the disease. In 1970, Broschetty and Cemoch' reported an improvement in patients with multiple sclerosis after treatment with hyperbaric oxygen. Since then the problem has been studied by several investigators.25 All have reported some improvement ranging from minimal to dramatic. In 1983 Fischer et al6 reported transient improvement among patients with multiple sclerosis treated with hyperbaric oxygen at a pressure of 2 atmospheres absolute for 90 minutes at a time during 20 exposures in a placebo-controlled double-blind randomised study. Furthermore, Procop et al7 and Warren et ar demonstrated in rodents that experimental allergic encephalomyelitis, an animal model for demyelinating disease, could be modified by hyperbaric oxygenation.
Evoked potentials are, in general, considered to be a good measure of conduction along myelinated fibre tracts and seem to follow the course of multiple sclerosis.9 To determine whether the latencies of visual evoked potentials (VEPs) change after treatment with hyperbaric oxygen and evaluate its clinical effect, a double-blind, placebo-controlled study was initiated.
Patients and methods

Patients
Twenty-four patients volunteered for the study after having its nature, purpose and risks explained to them. After the first compression four patients withdrew, one because of ear discomfort, and three because of claustrophobia. One patient could not continue the treatment because of alcoholism; he received only two treatments and was dropped from the follow-up. Thus, nineteen patients were included in the trial.
Age, sex, duration of the disease, Kurtzke' '2 13 Eleven patients were ambulatory and eight required the use of a wheelchair. The majority of patients had had a relapsing-remitting course in the beginning of the disease. All participants were, however, considered to have chronic progressive type of multiple sclerosis before entry to the study. The patients were assigned to the treatment (10 498 Age (yr) Clinical assessment was based on the numerical grading, ranging from zero (normal) to 10 (dead) on Kurzke's Disability Status Scale and Functional System Scale, the latter providing the numerical grading of pyramidal, cerebellar, brainstem, sensory, bowel-bladder, visual and mental functions. The assessment was performed by the same neurologist, unaware of the treatment being given, approximately one week before and one week after treatment.
Visual Evoked Potentials
VEPs were recorded between a midoccipital electrode 50 mm above the inion and a midfrontal electrode. EEG activity was analysed with a TOENNIES DA II R equip- The study protocol was approved by the local ethical committee.
Results
Clinical response
The results of clinical assessment, based on the Functional System Scale, are summarised in table 2. The changes in central nervous system functions, registered within one week after treatment, were usually slight. All but one of the patients moved only one step on the Functional System Scale. None improved or deteriorated to the extent that this could be registered on the Disability Status Scale. Improvement in bladder function was reported by two patients in the hyperbaric oxygen and by three patients in the control group. Improvement in brain stem function was noticed in one patient in the placebo group. Two patients improved in sensory All participants in the study were again clinically assessed 6 months after treatment. By this time, clinical signs indicating progression of the disease as compared to previous assessment, had appeared in four more patients. The deterioration, which was noticed in sensory, pyramidal and cerebellar systems, was again slight, not influencing the Functional System Scale more than one point. Two out of these four patients had been treated with hyperbaric oxygen. Side effects during hyperbaric oxygen treatment were noticed in only one patient who reported transient ear discomfort.
Visual evoked potentials P 100 latencies before, and changes recorded within one week after treatment, are given in table 3. VEPs recorded before treatment showed a slight prolongation in latency (110-125 ms) in one or both eyes in seven patients. A delay of more than 15 ms above the normal limit was recorded in both eyes in 10 patients. Responses could not be evoked in two patients. Only one out of all investigated eyes in 19 patients gave a normal P TM wave. The average latency in the treatment group was shorter than in the control group.
The individual changes in latencies after treatment were small. Using the criterion adopted by Matthews and Small, '6 defining 10 ms as the minimum value for changes of latency to be taken into account, none of the patients in the treatment group and only two patients in control group showed appreciable prolongation in VEP latencies. However, these changes were not correlated to clinical deterioration. After treatment the average VEP latency for the hyperbaric oxygen group was slightly shortened (-1.5 ms), whereas the control group showed an opposite tendency (+ 1-8 ms). The difference between the groups was not statistically significant (anais of variance, p > 0-05). The changes in P 100 amplitudes were very small in absolute values (0.5-6-0 ,V) and are not reported in this paper.
Discussion
All participants in this study had a well-established diagnosis of multiple sclerosis. The treatment and control groups were well matched with respect to age, duration of the disease, Disability Status Scale and Functional System Scale. After withdrawal of some patients and randomisation, the sex distribution and the average VEP latencies were somewhat uneven when comparing the treatment and control groups.
An association between the prolongation of latencies of evoked potentials and clinical progression has been suspected.977However, the method is not considered to be very sensitive in detecting clinical remissions. '6 Little is yet known as to how the treatment with hyperbaric oxygen influences the evoked potentials. An improvement of evoked potentials during the treatment in one patient has been reported by Hammond et al. '8 In our study the VEP recordings of all the patients demonstrated a delayed conduction in all but one eye before the treatment, reflecting the massive involvement of visual pathways by the disease. Furthermore, responses with ill-defined peaks made the exact determination of P TO difficult in many cases. The changes in the VEP latencies were slight and the differences between the groups negligible, suggesting a lack of effect of hyperbaric oxygen on the conduction along the visual pathways in this patient group.
The aetiology and pathogenesis of multiple sclerosis is still poorly understood. How hyperbaric oxygen could possibly influence the disease is discussed elsewhere.6 19 The clinical improvement reported by previous investigators ' 6 was not found in this trial. However, the majority of the previous studies were performed in multiplace chambers compressed with air and oxygen given to the patients by face mask. Due to leakage therefore, 100% oxygen was not delivered, as shown by arterial oxygen measurements.6 In this study single place chambers, where patients are treated in an atmosphere of compressed pure oxygen, were used and this difficulty was eliminated. Therefore the results of this study do not necessarily imply that more successful treatment at lower pressures is ruled out. The difficulties of establishing the effect of treatment in multiple sclerosis are well-known.202' The results of this study suggest that treatment with hyperbaric oxygen did not improve the clinical status in chronic progressive multiple sclerosis or stop the progression of the disease. However, our patient series were small and further studies, particularly with less affected patient groups and with variable pressure regimens, are needed to elucidate the role of hyperbaric oxygen in the treatment of multiple sclerosis.
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